Removal of thallium by deferasirox in rats as biological model
β Scribed by Amir Sh. Saljooghi; S. Jamiladin Fatemi
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 211 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0260-437X
- DOI
- 10.1002/jat.1573
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The present research aimed to characterize the potential efficiency of deferasirox in removing thallium after its administration for 30 days following two dose levels of 20 and 160βΞΌm of thallium (III) chloride to male Wistar rats every day. After thallium administration some abnormal clinical signs such as red staining around the eyes, greenish mottling on the liver, weakness, loss of hair and weight, were observed in animals. Deferasirox was given orally to different groups of rats for a period of one week immediately after thallium administration. After chelation therapy, animals were killed by exsanguination from the abdominal aorta, and then thallium and iron concentrations in various tissues were determined by standard addition method. The chelation therapy results showed that deferasirox was able to remove thallium ions from the body and clinical symptoms were also reduced. Copyright Β© 2010 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
## Abstract Lung metastases were observed in 80% to 85% of rats bearing advanced malignant bone tumours (osteogenic osteosarcomas and angiosarcomas). These tumours were induced in 2βmonthβold SpragueβDawley rats by inoculation of a colloidal suspension of radioactive cerium (^144^Ce) into the hind
Anatomical and functional information (renography, perfusion) was obtained by MRI in a life-supporting transplantation model, in which Lewis rats received kidneys from Fisher 344 donors. Renography and perfusion analyses were carried out with Gd-DOTA and small particles of iron oxide (SPIO), respect
Anti-tumor effects of TNF in animal models are well documented. Therapeutic use of TNF, however, is hampered by its toxicity. In rats a single intravenous (i.v.) injection of 40 pg/kg is lethal. When given by continuous i.v. infusion, much higher doses are well tolerated. To compare the therapeutic
An attempt was made to use the pineal gland as a model for the study of the primary mode of action of alpha-methyldopa, which is still unclear. Organ cultures of pineal glands from rats treated chronically with alpha-methyldopa showed enhanced conversion of radio-active serotonin to melatonin (aMT)